Imugene

About:

Imugene is a publicly-listed biotechnology company with operations in America and Europe,

Top Investors: Precision BioSciences

Description:

Imugene is a clinical-stage immuno-oncology firm researching a variety of innovative medicines that aim to engage cancer patients' immune systems in order to find and eradicate tumors. OnCARlytics (CF33-CD19) is a novel and successful combination immunotherapy that uses the CF33 oncolytic virus to deliver and show CD19 antigen on the surface of cancer cells, enabling CD19 CAR T cell anti-tumor responses against solid tumors.

Total Funding Amount:

$70.2M

Headquarters Location:

Sydney, New South Wales, Australia

Founded Date:

1986-01-01

Founders:

Number of Employees:

11-50

Last Funding Date:

2024-09-03

IPO Status:

Public

Industries: